読み込み中
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
前日終値
$21.11
+$0.66 · +3.23%
日中の時刻はETです。市場データは遅延する場合があります。
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
日中レンジ
現在 $21.11
52週レンジ
現在 $21.11
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
62
強気
リスク
50
やや高いリスク
モメンタム
63
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
日中レンジ
現在 $21.11
52週レンジ
現在 $21.11
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$48.83
上昇余地（131.31%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Biotechnology ETFIBB806.7万0.08%108.2億 USD0.44%$206.49+3.00%
AdvisorShares Psychedelics ETFPSIL194.29万4.15%4685.29万 USD1.84%$21.765+3.69%
iShares MSCI Ireland ETFEIRL107.9万1.44%7459.97万 USD0.50%$78.50-1.14%
Virtus Biotech Clinical Trials ETFBBC30.73万0.75%4099.65万 USD0.65%$44.1456+2.08%
Invesco Nasdaq Biotechnology ETFIBBQ10.8万0.10%1.12億 USD0.19%$34.62+2.96%
ProShares Ultra Nasdaq BiotechnologyBIB5.57万0.06%9320.36万 USD1.19%$110.98+5.68%
First Trust IPOX Europe Equity Opportunities ETFFPXE1.1万0.23%472.63万 USD0.70%$31.665-2.15%iShares Biotechnology ETFIBBAdvisorShares Psychedelics ETFPSILiShares MSCI Ireland ETFEIRLVirtus Biotech Clinical Trials ETFBBCInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBFirst Trust IPOX Europe Equity Opportunities ETFFPXEAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
